|
Aug 16
|
Plus Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Aug 15
|
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
|
|
Aug 15
|
We're Keeping An Eye On Plus Therapeutics' (NASDAQ:PSTV) Cash Burn Rate
|
|
Aug 14
|
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 14
|
Plus: Q2 Earnings Snapshot
|
|
Aug 14
|
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
|
|
Aug 14
|
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
|
|
Aug 6
|
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 5
|
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
|
|
Jul 31
|
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
|
|
Jul 23
|
Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
|
|
Jul 22
|
Leptomeningeal Metastases Market Research Report 2025-2035 | Competitive Analysis of Plus Therapeutics, AstraZeneca, AngioChem, and Y-mAbs Therapeutics
|
|
Jul 15
|
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
|
|
Jul 10
|
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
|
|
Jul 8
|
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
|
|
Jun 30
|
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
|
|
Jun 26
|
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
|
|
Jun 25
|
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
|
|
Jun 25
|
Sector Update: Health Care Stocks Advance Late Afternoon
|
|
Jun 25
|
Top Midday Gainers
|